Session Information

Session Moderator

15:45 - 15:46  |  Presenter: Tomaz Stupnik

Session Moderator

15:45 - 15:46  |  Presenter: Mir Alireza Hoda

ES12.01 - Session Introduction

15:45 - 15:46  |  Presenter: Tomaz Stupnik

ES12.02 - Session Introduction

15:46 - 15:47  |  Presenter: Mir Alireza Hoda

ES12.03 - The Role of Minimally Invasive Surgery in Multimodality Setting

15:47 - 15:59  |  Presenter: Alan D. L. Sihoe

ES12.04 - Surgical Challenges of Neoadjuvant Immunotherapy

15:59 - 16:11  |  Presenter: Valerie Williams Rusch

ES12.05 - Assessment of Resectability after Chemotherapy with Immunocheckpoint Inhibitor or Molecular Targeted Therapies

16:11 - 16:23  |  Presenter: Giulia Veronesi

ES12.06 - Optimum Surgical Staging and Tissue Acquisition for Adjuvant Immunotherapy and Targeted Treatments

16:23 - 16:35  |  Presenter: Paula A Ugalde Figueroa

ES12.07 - Live Q&A

16:35 - 16:45

Session Moderator

16:35 - 16:45  |  Presenter: Paolo Bironzo

Session Moderator

16:35 - 16:45  |  Presenter: Leah Backhus

ES13.01 - Session Introduction

15:45 - 15:46  |  Presenter: Paolo Bironzo

ES13.02 - Session Introduction

15:46 - 15:47  |  Presenter: Leah Backhus

ES13.03 - Update in the Pathologic Diagnosis in Mesothelioma

15:47 - 15:59  |  Presenter: Francoise Blanche Galateau Salle

ES13.04 - First Line Treatment: Optimal Choice for Which Patient?

15:59 - 16:11  |  Presenter: Wanda Cui

ES13.05 - Second Line and Beyond

16:11 - 16:23  |  Presenter: Dean Anthony Fennell

ES13.06 - Targeted Therapy and Experimental Drugs

16:23 - 16:35  |  Presenter: Raffit Hassan

ES13.07 - Live Q&A

16:35 - 16:45

Session Moderator

16:35 - 16:45  |  Presenter: Anne Fraser

Session Moderator

16:35 - 16:45  |  Presenter: Andreas Charalambous

ES14.01 - Session Introduction

15:45 - 15:46  |  Presenter: Anne Fraser

ES14.02 - Session Introduction

15:46 - 15:47  |  Presenter: Andreas Charalambous

ES14.03 - Information Needs of Carers of People with Lung Cancer

15:47 - 15:59  |  Presenter: Simon Dunne

ES14.04 - Interventions to Improve Cancer Survivorship among Indigenous Peoples and Communities

15:59 - 16:11  |  Presenter: Marianne Davies

ES14.05 - Interventions to Limit the Impacts of Parental Lung Cancer Impact on Children

16:11 - 16:23  |  Presenter: Elena Schiena

ES14.06 - Treating People with Comorbid Dementia: Implications for Cancer Care

16:23 - 16:35  |  Presenter: Lorna McWilliams

ES14.07 - Live Q&A

16:35 - 16:45

Session Moderator

16:40 - 16:45  |  Presenter: Navneet Singh

Session Moderator

16:40 - 16:45  |  Presenter: Khaled Abdel-Aziz Mohamed Kamal

ES15.01 - Session Introduction

15:45 - 15:46  |  Presenter: Navneet Singh

ES15.02 - Session Introduction

15:46 - 15:47  |  Presenter: Khaled Abdel-Aziz Mohamed Kamal

ES15.03 - Impact of Smoking on Clinical Outcomes of Systemic Therapies

15:47 - 15:52  |  Presenter: Enrica Capelletto

ES15.04 - Can Chemotherapy Agents Be Personalized in NSCLC?

15:52 - 16:04  |  Presenter: David Planchard

ES15.05 - Second-Line Chemotherapy Following First-Line Mono-Immunotherapy in High PD-L1 (TPS≥50%) Advanced/Metastatic NSCLC

16:04 - 16:16  |  Presenter: Sara Pilotto

ES15.06 - The Future of Cytotoxics in the Management of NSCLC

16:16 - 16:28  |  Presenter: Sofia Baka

ES15.07 - Chemotherapy in Elderly NSCLC Patients: How to Play It Safe?

16:28 - 16:40  |  Presenter: Rajwanth Veluswamy

ES15.08 - Live Q&A

16:40 - 16:45

Session Moderator

15:45 - 15:45  |  Presenter: Luis Paz-Ares

Session Moderator

15:45 - 15:45  |  Presenter: Tina Cascone

MA05.01 - Session Introduction

15:45 - 15:46  |  Presenter: Luis Paz-Ares

MA05.02 - Session Introduction

15:46 - 15:47  |  Presenter: Tina Cascone

MA05.03 - Utilization of Genomic Mutation Signature to Predict the Immunotherapy Response in Non-small Cell Lung Cancer

15:47 - 15:52  |  Presenter: Wenbin Li

MA05.04 - Multiplex Phenotyping Reveals Spatial Immune Patterns in NSCLC

15:52 - 15:57  |  Presenter: Max Wilhelm Backman

MA05.05 - Analysis of CREBBP as a Potential Biomarker for Immune Checkpoint Therapy in Solid Tumors and Its Correlation With Immune Microenvironment

15:57 - 16:02  |  Presenter: Xiaoli Liu

MA05.06 - Discussant

16:02 - 16:12  |  Presenter: Fabio Pagni

MA05.07 - Intertumoral Molecular Heterogeneity of Non-small Cell Lung Cancer With MET Exon 14 Skipping

15:57 - 16:02  |  Presenter: Yuchen Han

MA05.08 - MET Exon 14 Skipping Mutation in Non-Small Cell Lung Cancer (NSCLC) by Specific Mutation, Histology, and Smoking History

16:17 - 16:22  |  Presenter: Jennifer A. Marks

MA05.09 - Genomic Mapping of Metastatic Organotropism: Analysis of 2326 Primary and Organ-Specific Metastases in Lung Adenocarcinoma

16:22 - 16:27  |  Presenter: Harry Lengel

MA05.10 - Discussant

16:27 - 16:37  |  Presenter: Giulia Pasello

MA05.11 - Live Q&A

16:37 - 16:45

Session Moderator

16:27 - 16:37  |  Presenter: Arjun Nair

Session Moderator

16:27 - 16:37  |  Presenter: Ella A Kazerooni

OA05.01 - Session Introduction

15:45 - 15:46  |  Presenter: Arjun Nair

OA05.02 - Session Introduction

15:46 - 15:47  |  Presenter: Ella A Kazerooni

OA05.03 - Incidence, Timing, and Survival of Second Primary Lung Cancer in Patients in the National Lung Screening Trial

15:47 - 15:57  |  Presenter: Alexandra Potter

OA05.04 - A Comparison of Stage- and Histology-Specific CT Sensitivity in the NELSON Trial and the NLST

15:57 - 16:07  |  Presenter: Koen de Nijs

OA05.05 - China Lung Cancer Screening (CLUS) Version 1.0: Mortality, Survival and Incidence Rates with Long-Term Follow-up

16:07 - 16:17  |  Presenter: Fangfei Qian

OA05.06 - Early Diagnosis of Lung Cancer Among Younger vs. Older Adults: Widening Disparities in the Era of Lung Cancer Screening

16:17 - 16:27  |  Presenter: Alexandra Leigh Potter

OA05.07 - Discussant

16:27 - 16:37  |  Presenter: Anand Devaraj

OA05.08 - Live Q&A

16:37 - 16:45

EP01.01-001 - Circulating Tumor Cells-Based Radiobiological Model Improves the Indeterminate Pulmonary Solid Nodules Diagnosis

EP01.01-002 - Challenges in the Use of NLST Image Data for Quantitative Algorithm Development

EP01.01-003 - DELFI-L101: Development of a Blood-Based Assay That Evaluates Cell-Free DNA Fragmentation Patterns to Detect Lung Cancer

EP01.01-004 - The Correlation Between Exhaled Volatile Organic Compounds Using Breath Analyzer and Interleukin-23 (IL-23) in Lung Cancer

EP01.01-005 - Increased Levels of mRNAs and miRNAs Associated with Imminent and Advanced Lung Cancer

EP01.01-006 - Sensitive Detection of Lung Cancer Using a Multiomic Plasma Cell-Free DNA Sequencing Assay

EP01.01-007 - Incorporating cfDNA Detection to CT Scan Assessment in Post-Surgical Lung Cancer Patients

EP01.01-008 - Expression of PD-L1 mRNA and Its Epigenetic Regulators: MicroRNA-17, -93 and -142 in Early Stages NSCLC Patients’ Plasma

EP01.01-009 - Common MicroRNAs in Pre-diagnostic Serum Associated with Lung Cancer in Two Cohorts up to Eight Years Before Diagnosis: A HUNT Study

EP01.01-010 - Graphene Based Activity Sensors Detect All Stages of Lung Cancer Using an Evolutionary Machine Learning Algorithm Approach

EP01.01-011 - Utility of Arm-level cfDNA Fragment Size Distribution in the Early Detection of Lung Cancer and Pan Cancer

EP01.01-012 - Clinical and Molecular Features of Chinese Early-stage Multiple Primary Lung Cancer Patients

EP01.02-001 - Citizens’ Perspective on Combination Screening for Lung Cancer, COPD and CVD

EP01.02-002 - Awareness of Palestinians about Lung Cancer Symptoms: A National Cross-sectional Study

EP01.02-003 - Lung Cancer Screening: A Systematic Review of Knowledge Translation Interventions

EP01.02-004 - Education Messages and Strategies About Lung Cancer Screening: A Systematic Review

EP01.02-005 - Exploring Individuals' Views on Invitation to Lung Cancer Screening: Developing a Tailored Approach

EP01.02-006 - Excuse Me? Patient Perceptions of Lung Cancer Screening Results

EP01.02-007 - It’s Not How You Start, It’s How You Finish: Patient Motivators to Follow Low-Dose Screening Recommendations

EP01.02-008 - Pocket Nodules, An Innovative Patient Education Tool to Explain Lung Nodules

EP01.03-001 - Māori Perspectives on a Potential Lung Cancer Screening Programme Aotearoa NZ: An Indigenous People’s Perspective.

EP01.03-002 - Implementation of the International Lung Screen Trial (ILST) in Catalonia: A Cost Analysis study

EP01.03-003 - AI Detection of Emphysema in an Ultra-Low Dose CT Lung Cancer Screening Program

EP01.03-004 - Should We Screen for Lung Cancer? A 10-Country Analysis Identifying Key Decision-Making Factors

EP01.03-005 - Current status of High-risk Smokers Participating in Population-based National Lung Cancer Screening Program in Korea

EP01.03-006 - Potential Drivers of Lung Cancer Screening Participation in Australia: A Qualitative Study to Inform Future Implementation

EP01.03-007 - Lung Cancer Screening Use Among Screening-Eligible Adults With Disability in the United States: Evidence From Population-Based Data

EP01.03-008 - Lung Cancer Screening Patients Experiences and Satisfaction: Quantitative and Qualitative Findings From a Survey Study

EP01.03-009 - Cost-effectiveness of Lung Cancer Screening in New Zealand Varies by Ethnicity

EP01.03-010 - China Lung Cancer Screening Study (CLUS) Version 2.0: Study Design and Baseline Screening Results

EP01.03-011 - Clinical Features and Surgical Outcomes of Young Patients with Ground Glass Opacity Featured Lung Adenocarcinoma

EP01.03-012 - Acceptability and Feasibility of Lung Cancer Screening in Australia: The View of Key Stakeholders

EP01.03-013 - A Pilot Study of Lung Cancer Screening with Low Dose CT in Georgia (One Centre Experience and Preliminary Data).

EP01.04-001 - A Programmatic Approach to Improve Efficiency in Lung Cancer Screening

EP01.04-002 - The Impact of Enforcing a Structure in Lung Cancer Screening Strategy on the Effectiveness and Efficiency of the Screening Program

EP01.04-003 - Effectiveness of Cloud-based Computer Aided Quality Control System in Korean National Lung Cancer Screening

EP01.04-004 - Overcoming the Barriers to Lung Cancer Screening using a Systemwide Approach

EP01.04-005 - Quantitative Characteristics in Global CT Lung Cancer Screening Populations Using the ELIC Distributed Database and Computation Environment

EP01.04-006 - Clinical Scores, Biomarkers and It Tools in Lung Cancer Screening - Can an Integrated Approach Overcome Current Challenges?